Patents by Inventor Scott A. Bone

Scott A. Bone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1- methylcyclohexane-1-carboxamide
    Patent number: 11701362
    Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: July 18, 2023
    Assignee: Celgene Corporation
    Inventors: Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
  • COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA
    Publication number: 20230201175
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Application
    Filed: December 30, 2022
    Publication date: June 29, 2023
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA
    Publication number: 20230201176
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Application
    Filed: March 6, 2023
    Publication date: June 29, 2023
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
    Patent number: 11612591
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: March 28, 2023
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Amorphous kinase inhibitor formulations and methods of use thereof
    Patent number: 11576903
    Abstract: Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: February 14, 2023
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF
    Publication number: 20220265622
    Abstract: Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Application
    Filed: May 3, 2022
    Publication date: August 25, 2022
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF
    Publication number: 20220265623
    Abstract: Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Application
    Filed: May 3, 2022
    Publication date: August 25, 2022
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA
    Publication number: 20220257574
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Application
    Filed: May 3, 2022
    Publication date: August 18, 2022
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
    Patent number: 11395818
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: July 26, 2022
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF
    Publication number: 20220031677
    Abstract: Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Application
    Filed: October 18, 2021
    Publication date: February 3, 2022
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Amorphous kinase inhibitor formulations and methods of use thereof
    Patent number: 11185535
    Abstract: Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: November 30, 2021
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF
    Publication number: 20210196692
    Abstract: Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Application
    Filed: February 19, 2021
    Publication date: July 1, 2021
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA
    Publication number: 20210196693
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Application
    Filed: February 19, 2021
    Publication date: July 1, 2021
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • COMPOSITIONS AND METHODS OF USE OF CIS-4-[2-{[(3S,4R)-3-FLUOROOXAN-4-YL]AMINO}-8-(2,4,6-TRICHLOROANILINO)-9H-PURIN-9-YL]-1-METHYLCYCLOHEXANE-1-CARBOXAMIDE
    Publication number: 20210128564
    Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Application
    Filed: December 22, 2020
    Publication date: May 6, 2021
    Inventors: Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
  • Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
    Patent number: 10898488
    Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: January 26, 2021
    Assignee: Celgene Corporation
    Inventors: Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
  • COMPOSITIONS AND METHODS OF USE OF CIS-4-[2-{[(3S,4R)-3-FLUOROOXAN-4-YL]AMINO}-8-(2,4,6-TRICHLOROANILINO)-9H-PURIN-9-YL]-1-METHYLCYCLOHEXANE-1-CARBOXAMIDE
    Publication number: 20200237767
    Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Application
    Filed: April 10, 2020
    Publication date: July 30, 2020
    Inventors: Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
  • Compositions and methods of use of cis-4-[2-{[3S,4R)-3-fluorooxan-4-yl]amino}8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
    Patent number: 10653697
    Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: May 19, 2020
    Assignee: Celgene Corporation
    Inventors: Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
  • COMPOSITIONS AND METHODS OF USE OF CIS-4-[2-{[(3S,4R)-3-FLUOROOXAN-4-YL]AMINO}-8-(2,4,6-TRICHLOROANILINO)-9H-PURIN-9-YL]-1-METHYLCYCLOHEXANE-1-CARBOXAMIDE
    Publication number: 20200113908
    Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 16, 2020
    Inventors: Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
  • Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
    Patent number: 10543214
    Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: January 28, 2020
    Assignee: Celgene Corporation
    Inventors: Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
  • COMPOSITIONS AND METHODS OF USE OF CIS-4-[2-{[(3S,4R)-3-FLUOROOXAN-4-YL]AMINO}-8-(2,4,6-TRICHLOROANILINO)-9H-PURIN-9-YL]-1-METHYLCYCLOHEXANE-1-CARBOXAMIDE
    Publication number: 20190099425
    Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Application
    Filed: October 3, 2018
    Publication date: April 4, 2019
    Inventors: Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang